Liposomal nanocarriers for plasminogen activators
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
26876783
DOI
10.1016/j.jconrel.2016.02.019
PII: S0168-3659(16)30072-4
Knihovny.cz E-zdroje
- Klíčová slova
- Fibrin, Liposomes, Platelets, Protein delivery, RGD peptide, Streptokinase, Stroke, Thrombus, Tissue plasminogen activator, Urokinase,
- MeSH
- aktivátor plazminogenu urokinázového typu aplikace a dávkování terapeutické užití MeSH
- fibrinolytika aplikace a dávkování terapeutické užití MeSH
- lidé MeSH
- liposomy chemie ultrastruktura MeSH
- metaloendopeptidasy aplikace a dávkování terapeutické užití MeSH
- nanostruktury chemie ultrastruktura MeSH
- plasmin aplikace a dávkování terapeutické užití MeSH
- streptokinasa aplikace a dávkování terapeutické užití MeSH
- tkáňový aktivátor plazminogenu aplikace a dávkování terapeutické užití MeSH
- tromboembolie farmakoterapie MeSH
- trombolytická terapie metody MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- aktivátor plazminogenu urokinázového typu MeSH
- auR protein, Staphylococcus aureus MeSH Prohlížeč
- fibrinolytika MeSH
- liposomy MeSH
- metaloendopeptidasy MeSH
- plasmin MeSH
- streptokinasa MeSH
- tkáňový aktivátor plazminogenu MeSH
Several plasminogen activators (PAs) have been found effective in treating different thromboembolic diseases. However, administration of conventional thrombolytic therapy is limited by a low efficacy of present formulations of PAs. Conventional treatments using these therapeutic proteins are associated with several limitations including rapid inactivation and clearance, short half-life, bleeding complications or non-specific tissue targeting. Liposome-based formulations of PAs such as streptokinase, tissue-plasminogen activator and urokinase have been developed to improve the therapeutic efficacy of these proteins. Resulting liposomal formulations were found to preserve the original activity of PAs, promote their selective delivery and improve thrombus targeting. Therapeutic potential of these liposome-based PAs has been demonstrated successfully in various pre-clinical models in vivo. Reductions in unwanted side effects (e.g., hemorrhage or immunogenicity) as well as enhancements of efficacy and safety were achieved in comparison to currently existing treatment options based on conventional formulations of PAs. This review summarizes present achievements in: (i) preparation of liposome-based formulations of various PAs, (ii) development of PEGylated and targeted liposomal PAs, (iii) physico-chemical characterization of these developed systems, and (iv) testing of their thrombolytic efficacy. We also look to the future and the imminent arrival of theranostic liposomal formulations to move this field forward.
Citace poskytuje Crossref.org
